Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma

New England Journal of Medicine

Volumn 374, Issue 14, 2016, Pages 1344-1355

  Buckner, Jan C ^a   Shaw, Edward G ^b   Pugh, Stephanie L ^d   Chakravarti, Arnab ^e   Gilbert, Mark R ^g   Barger, Geoffrey R ^h   Coons, Stephen ⁱ   Ricci, Peter ^k   Bullard, Dennis ^c   Brown, Paul D ^g   Stelzer, Keith ^l   Brachman, David ^j   Suh, John H ^f   Schultz, Christopher J ^m   Bahary, Jean Paul ^a   Fisher, Barbara J ^n,o   Kim, Harold ^h   Murtha, Albert D ^p   Bell, Erica H ^e   Won, Minhee ^d   Mehta, Minesh P ^q   Curran, Walter J ^r   more..

^a MAYO CLINIC   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c Triangle Neurosurgeons ^*  (United States)

^d NRG ONCOLOGY STATISTICS AND DATA MANAGEMENT CENTER   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h WAYNE STATE UNIVERSITY   (United States)

ⁱ BARROW NEUROLOGICAL INSTITUTE   (United States)

^j Arizona Oncology Services   (United States)

^k Radiology Imaging Associates   (United States)

^l NewYork Presbyterian Hospital   (United States)

^m MEDICAL COLLEGE OF WISCONSIN   (United States)

ⁿ CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^o LONDON REGIONAL CANCER PROGRAM   (Canada)

^p CROSS CANCER INSTITUTE   (Canada)

^q UNIVERSITY OF MARYLAND   (United States)

^r EMORY UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LOMUSTINE; PROCARBAZINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; AGE; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTROCYTOMA; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; COHORT ANALYSIS; CONSTIPATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION; KARNOFSKY PERFORMANCE STATUS; LEUKEMIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; NEUTROPENIA; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SUBTOTAL TUMOR RESECTION; THROMBOCYTOPENIA; TOXIC HEPATITIS; TUMOR BIOPSY; BRAIN NEOPLASMS; CANCER GRADING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MORTALITY; MULTIMODALITY CANCER THERAPY; PHASE 3 CLINICAL TRIAL; SURVIVAL; YOUNG ADULT;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTROCYTOMA; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOMUSTINE; MALE; NEOPLASM GRADING; OLIGODENDROGLIOMA; PROCARBAZINE; SURVIVAL ANALYSIS; VINCRISTINE; YOUNG ADULT;

EID: 84963804957     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1500925     Document Type: Article

References (16)

1. Cairncross G, Macdonald D, Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 1994; 12: 2013-21.
2. Buckner JC, Brown LD, Kugler J W, et al. Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma. J Neurosurg 1995; 82: 430-5.
3. Galanis E, Buckner JC, Burch PA, et al. Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results. J Clin Oncol 1998; 16: 2953-8.
4. Mason WP, Krol GS, DeAngelis LM. Low-grade oligodendroglioma responds to chemotherapy. Neurology 1996; 46: 203-7.
5. Buckner JC, Gesme D Jr, O'Fallon JR, et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol 2003; 21: 251-5.
6. Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer 2005; 103: 802-9.
7. Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vin-cristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol 2012; 30: 3065-70.
8. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
9. Klein J, Moeschberger M. Survival analysis: techniques for censored and truncated data. New York: Springer, 2003.
10. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-70.
11. Cox DR Regression models and life-tables. J R Stat Soc [B] 1972; 34: 187-220.
12. Fu KK, Pajak TF, Marcial VA, et al. Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: long-term follow-up results of RTOG 83-13. Int J Radiat Oncol Biol Phys 1995; 32: 577-88.
13. Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98-02. J Clin Oncol 2014; 32: 535-41.
14. Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol 2014; 32: 783-90.
15. van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligoden-droglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013; 31: 344-50.
16. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006; 66: 9852-61.